OM Pharma will unveil preliminary REACH real-world evidence results for Broncho-Vaxom OM-85 at EAACI 2026, showing that the oral bacterial lysate was associated with a 28% to 38% reduction in respiratory tract infection rates at 12 months and a 29% to 41% reduction at 24 months after treatment initiation. The largest multi-country real-world evidence study to date for Broncho-Vaxom OM-85 evaluated 15,794 pediatric, adolescent, adult and elderly patients in China, Italy and Belgium, positioning the data as a potentially important field-practice test for recurrent respiratory tract infection prevention.
The more important issue is not whether Broncho-Vaxom OM-85 has suddenly become a new product story. It has not. The more meaningful question is whether OM Pharma can use a large, multi-country observational dataset to strengthen confidence in a preventive respiratory infection strategy that sits between conventional symptomatic care, antibiotic stewardship and immune-focused disease management. For clinicians, the result may be less about replacing existing care and more about deciding whether an oral immunomodulator has enough real-world consistency to become a more structured part of recurrent respiratory tract infection prevention.
Why a large real-world evidence dataset matters more than another narrow efficacy signal
The REACH study matters because recurrent respiratory tract infections are not a neat, single-pathway problem. Patients differ by age, infection frequency, comorbidities, healthcare access, diagnostic coding and prescribing behaviour. A product that looks encouraging in a controlled trial can still face adoption friction if clinicians are unsure whether the same benefit appears in everyday practice, especially across children, working-age adults and elderly patients.
That is where the scale of REACH becomes strategically relevant. A 15,794-patient cohort gives OM Pharma a broader evidence base than a small, tightly controlled respiratory study, particularly because the dataset spans China, Italy and Belgium. This geographic range gives the readout more practical weight, as it captures different healthcare systems, patient behaviours and treatment environments. It also gives payers and respiratory specialists something they often ask for in preventive therapy discussions: evidence that moves beyond idealised trial conditions.
The limitation is just as important. Real-world evidence can reveal patterns, durability and healthcare utilisation effects, but it does not automatically answer every causality question. Because REACH includes secondary data drawn from routine healthcare systems, the analysis depends heavily on data quality, coding consistency, patient matching and adjustment for confounding factors. The first endpoint compares infection rates before and after OM-85 initiation, which is useful but inherently vulnerable to regression to the mean, changes in patient behaviour and seasonal infection patterns. The pending second primary endpoint, which evaluates matched untreated cohorts, is therefore the more decisive test for how strongly the dataset can support comparative effectiveness.
What the REACH study changes for clinicians assessing recurrent respiratory infections
For clinicians, the most practical signal is that Broncho-Vaxom OM-85 was associated with lower respiratory tract infection recurrence over both 12 and 24 months. That duration matters because recurrent respiratory infections are not judged only by short-term symptom control. The clinical burden is cumulative, with repeated medical visits, antibiotic exposure, school absence, work disruption, caregiver pressure and quality-of-life erosion shaping how patients and families experience the condition.
The reported reductions across age subgroups also matter because recurrent respiratory infections are often discussed differently in children, adults and elderly patients. Pediatric use raises questions about immune development, school-related infection cycles and caregiver demand. Adult use raises productivity and comorbidity questions. Elderly use introduces vulnerability, polypharmacy and respiratory reserve concerns. A cross-age signal does not erase those differences, but it gives clinicians a more unified evidence frame when considering whether OM-85 may have a role in prevention.
The unresolved issue is whether the measured reductions translate into treatment algorithms in a consistent way. Clinicians will want to know which patients benefit most, whether baseline infection frequency modifies effect size, how comorbid asthma or chronic bronchitis changes the risk-benefit calculation, and whether reduced medical visits also mean lower antibiotic prescribing. Without that granularity, the data strengthen the conversation but do not fully settle patient selection.
Why non-antibiotic prevention is becoming a sharper commercial and clinical priority
Broncho-Vaxom OM-85 sits in a clinically relevant but commercially tricky category. It is not an antibiotic, not a vaccine in the conventional pathogen-specific sense, and not a biologic targeting a single inflammatory pathway. It is an oral bacterial lysate designed to train and strengthen immune defences against recurrent respiratory infections. That positioning is attractive because healthcare systems are under pressure to reduce unnecessary antibiotic use, especially in respiratory conditions where prescribing can be high even when bacterial infection is uncertain.
This gives OM Pharma a credible stewardship narrative. If a preventive therapy reduces infection episodes that trigger physician visits, it could indirectly reduce downstream antibiotic exposure, healthcare utilisation and patient disruption. That is commercially meaningful because healthcare systems increasingly value interventions that reduce avoidable demand rather than only treating acute episodes after they occur.
However, the category still faces perception challenges. Bacterial lysate therapies are familiar in some markets but less embedded in others. Physicians who are comfortable with inhaled therapies, antibiotics, vaccines and guideline-driven asthma or chronic obstructive pulmonary disease management may need clearer mechanistic and outcomes-based evidence before changing practice patterns. Payers may also ask whether the observed reduction in infections produces measurable savings after accounting for product cost, repeat use and patient adherence.
What is genuinely new versus incremental in the Broncho-Vaxom evidence package
The new element is not the existence of OM-85 as a preventive respiratory infection therapy. Broncho-Vaxom has a long history of use across multiple markets, and the broader OM-85 literature already includes randomized trials, systematic reviews and analyses in pediatric and adult respiratory settings. The new element is the scale and real-world structure of REACH, especially its multi-country design, broad age coverage and long follow-up windows.
That makes the announcement incremental scientifically but potentially more important operationally. Incremental evidence can still be highly valuable when a product category has historical familiarity but uneven adoption. For OM Pharma, the study may help bridge a gap between clinical literature and everyday decision-making by showing that the therapy’s effect appears in routine healthcare data, not only in controlled research settings.
The risk is that industry observers may treat the preliminary readout as supportive rather than practice-changing until the matched untreated analysis is available. Before-and-after reductions are useful, but comparative analyses against similar non-users are more persuasive for clinicians, regulators and payers. The second endpoint could either reinforce the current signal or narrow its interpretation, depending on how well treated and untreated cohorts are balanced.
How Broncho-Vaxom compares with current respiratory infection prevention strategies
Current management of recurrent respiratory tract infections often involves a patchwork of vaccination where appropriate, risk-factor management, symptomatic treatment, treatment of underlying airway disease, and antibiotics when bacterial infection is suspected or confirmed. In patients with chronic airway disease, clinicians may also consider inhaled therapies, macrolide strategies in selected cases, or anti-inflammatory approaches depending on the underlying diagnosis.
Broncho-Vaxom OM-85 is differentiated by aiming upstream of acute treatment. Its value proposition is preventive immune conditioning rather than episode-by-episode management. That could make it appealing for patients who repeatedly cycle through medical consultations and antimicrobial exposure, especially where recurrent infections trigger exacerbations of broader airway disease.
The limitation is that prevention markets require a higher behavioural commitment than acute treatment markets. Patients must take therapy when they may not be acutely ill, clinicians must identify appropriate candidates before another infection episode occurs, and payers must be convinced that prevention lowers downstream burden. The REACH data help answer part of that question, but adoption will depend on how convincingly OM Pharma links fewer infection episodes with fewer physician visits, lower antibiotic use and measurable health system savings.
Why regulators and payers will scrutinise the design before accepting broader claims
The regulatory significance of REACH is likely to be indirect rather than immediate. Real-world evidence can support label discussions, post-marketing confidence, payer dossiers and guideline debates, but its impact depends on design transparency. Because REACH used secondary healthcare data, stakeholders will focus on definitions of respiratory tract infection episodes, inclusion criteria, baseline infection burden, follow-up completeness, country-specific coding practices and statistical handling of confounders.
The pre-post endpoint is clinically intuitive because it asks whether patients had fewer infections after starting OM-85 than before. That is easy for physicians and patients to understand. However, regulators and health technology assessment bodies often prefer comparative evidence, especially when observational data are used to support effectiveness claims. The matched untreated cohort analysis therefore becomes the pivotal next layer.
For OM Pharma, this creates both opportunity and risk. If the second primary endpoint aligns with the first, the REACH programme could become a stronger external validation tool for medical affairs, payer engagement and clinician education. If the comparative endpoint is less robust, the current result may still support routine-practice relevance but with narrower language around association rather than causal benefit.
What adoption barriers could still slow Broncho-Vaxom’s commercial momentum
Even strong real-world evidence does not guarantee immediate uptake. Broncho-Vaxom OM-85 will need to fit into local treatment pathways, reimbursement systems and physician habits. Respiratory infection prevention is a crowded behavioural space, not because many products do exactly the same thing, but because clinicians already manage these patients through layered interventions such as vaccination, airway control, hygiene counselling, allergy management and selective antibiotic use.
A key commercial challenge is segmentation. OM Pharma will need to show which patients should be prioritised: children with frequent respiratory infections, adults with repeated physician visits, elderly patients at high burden, or patients with respiratory comorbidities such as asthma or chronic bronchitis. Broad indication language can help market access, but precision in patient selection often drives real-world adoption.
Manufacturing and scalability appear less problematic than they would be for a novel cell therapy, biologic or complex diagnostic platform, but global consistency still matters. Bacterial lysate therapies require confidence in product standardisation, quality control and reliable supply across markets. As evidence expectations rise, manufacturing credibility becomes part of the clinical trust equation, not merely a back-office issue.
What industry observers are likely to watch after the EAACI 2026 presentation
The most closely watched follow-up will be the matched untreated cohort analysis. That result will determine whether the REACH study remains a large supportive dataset or becomes a more forceful comparative evidence package. Clinicians will also look for subgroup detail, especially whether benefit differs by age, prior infection frequency, country, respiratory comorbidity and baseline healthcare utilisation.
Another important watchpoint is antibiotic use. The release frames recurrent respiratory infections as a driver of healthcare burden and antibiotic prescribing pressure, but the most commercially persuasive prevention argument would be stronger if OM Pharma can show reductions in antibiotic prescriptions or infection-related consultations alongside lower episode rates. In an antimicrobial resistance-sensitive environment, that would make the data more relevant to payers and policy stakeholders.
Industry observers will also track whether the data influence guideline discussions. Broncho-Vaxom OM-85 already has clinical literature behind it, but guideline adoption usually depends on consistency, quality and applicability of evidence. REACH gives OM Pharma a larger routine-practice argument, but guideline committees will likely weigh it alongside randomized evidence, meta-analyses and local healthcare priorities.
Why the REACH readout strengthens OM Pharma’s case without closing the debate
OM Pharma’s REACH study gives Broncho-Vaxom OM-85 a meaningful evidence boost because it addresses a real weakness in many preventive therapies: whether controlled-study effects survive in routine care. The scale, multi-country design and broad age range make the readout more useful than a narrow conference signal, and the 12-month and 24-month reductions provide a durability angle that clinicians will notice.
The study also arrives at a strategically favourable moment. Healthcare systems are looking for ways to reduce avoidable respiratory burden, physicians are under pressure to prescribe antibiotics more judiciously, and patients with recurrent infections often sit in a frustrating grey zone between acute treatment and long-term prevention. Broncho-Vaxom OM-85 can speak to that gap in a way that is clinically relevant and commercially coherent.
Still, the strongest conclusion is measured rather than dramatic. The REACH study reinforces the rationale for Broncho-Vaxom OM-85 as a preventive option in recurrent respiratory tract infections, but the pending comparative endpoint will decide how far the evidence can travel with regulators, payers and guideline bodies. For now, OM Pharma has strengthened the case for bacterial lysate therapies in real-world respiratory care. The next test is whether the full dataset can turn that strengthened case into broader clinical confidence.
Could OM Pharma’s Broncho-Vaxom study change how clinicians assess recurrent RTI prevention? added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →